STOCK TITAN

SPRCY - SPRCY STOCK NEWS

Welcome to our dedicated page for SPRCY news (Ticker: SPRCY), a resource for investors and traders seeking the latest updates and insights on SPRCY stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SPRCY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SPRCY's position in the market.

Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) announced the formation of a joint venture, MitoCareX Bio Ltd., to focus on discovering and developing drugs for cancer and other serious conditions. The new Israeli-based company will explore the role of mitochondrial carriers in treating life-threatening diseases. SciSparc plans to invest up to $1.7 million over two years for a 50.01% stake, contingent on specific milestones. The initiative aims to leverage advanced drug discovery techniques and prior successful experiments in the UK, with expert Professor Ciro Leonardo Pierri advising the program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 8:30 a.m. EST. The conference runs from February 23-25, 2022. Interested parties can access the presentation by requesting it from Aegis during the conference dates. The slide deck will also be available on SciSparc's website. The company is focused on cannabinoid pharmaceuticals, with drug development programs targeting disorders such as Tourette syndrome, obstructive sleep apnea, and autism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) announced a new leadership team effective January 10, 2022. Oz Adler has been appointed CEO, while Itschak Shrem becomes President and Amitay Weiss is named Chairman of the Board. Adler has been with the company since September 2017, serving as CFO since April 2018. Weiss joined in August 2020, previously working at Bank Poalei Agudat Israel Ltd. Shrem has been Chairman since August 2020 and has extensive experience in financial markets. SciSparc focuses on developing cannabinoid-based pharmaceuticals for conditions like Tourette syndrome and Alzheimer's disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has announced an agreement with Hannover Medical School and Tel-Aviv Sourasky Medical School to advance its Phase IIb clinical study for SCI-110, a drug aimed at treating Tourette syndrome. The study will be led by renowned experts and is a double-blind, placebo-controlled trial evaluating SCI-110's efficacy and safety for adults aged 18-65. SCI-110 combines dronabinol with palmitoylethanolamide and is developed to enhance THC effectiveness while reducing side effects. The study aims to address the unmet medical need for effective treatments in Tourette syndrome, a condition affecting approximately 1% of the global population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) has initiated an examination of psychedelic compounds as potential additions to its intellectual property portfolio. The growing interest in psychedelics could align with the company's focus on disorders of the central nervous system. A report suggests the psychedelic therapy market may reach over $10 billion by 2027, up from $4.75 billion in 2020. Chief Technologies Officer Adi Zuloff-Shani expressed optimism about the compatibility of psychedelic compounds with the company's existing drug development programs, which target conditions such as Tourette syndrome and Alzheimer's disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) announced the recruitment of its first patient for a Phase IIa clinical trial investigating the safety, tolerability, and efficacy of SCI-110 in treating Alzheimer's disease and associated agitation. Conducted at the Israeli Medical Center for Alzheimer's, the trial aims to provide an efficient treatment option amid limited existing therapies. SCI-110 combines synthetic Δ⁹-THC and Palmitoylethanolamide to address behavioral disturbances commonly observed in Alzheimer's patients, with the hope of improving their quality of life.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

SciSparc Ltd. (NASDAQ: SPRC) announced a significant milestone with the granting of U.S. Patent No. 11,207,290, covering cannabinoid and N-acylethanolamine combinations for treating central nervous system disorders. This achievement is deemed crucial for the company, as it strengthens their intellectual property portfolio, now comprising four U.S. patents, along with similar patents in Australia and Japan. The patent emphasizes the uniqueness of their methodologies and compounds, reinforcing SciSparc's commitment to developing effective treatments for patients facing currently untreatable conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (OTCQB: SPRCY), a clinical-stage pharmaceutical company, has completed its corporate rebranding, unveiling a new name, logo, and website. This rebranding aligns with its focus on developing cannabinoid-based treatments for various CNS disorders. The company is actively pursuing four drug candidates in clinical trials for conditions including Tourette Syndrome and Alzheimer's Disease. Additionally, it announced the start of a Phase IIa trial for SCI-110 targeting Alzheimer's-related agitation, following recent approvals from health authorities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

SciSparc Ltd. (OTCQB: SPRCY) reported positive top-line results from a pre-clinical trial of its compound SCI-160 for treating neuropathic and post-operative pain. The study demonstrated significant pain relief for up to 7 days post-surgery and highlighted the potential of SCI-160 as a non-opioid alternative for pain management. Key findings include significant pain alleviation within 6 hours of injection and prolonged effects in conjunction with palmitoylethanolamide (PEA). The global postoperative pain management market is projected to reach $45 billion by 2026, emphasizing the compound's market potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

SciSparc Ltd. (OTCQB: SPRCY) announced updates regarding its Phase IIb clinical study for Tourette Syndrome using its cannabinoid-based treatment, SCI-110. The company has engaged a contract research organization to support the trial and established its supply chain for drug manufacturing. Two clinical sites are identified for the study, which will evaluate SCI-110's efficacy, safety, and tolerability through a randomized, double-blind, placebo-controlled approach. The primary objectives will assess the treatment's impact on tic severity and monitor Serious Adverse Events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
SPRCY

OTC:SPRCY

SPRCY Rankings

SPRCY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link